Literature DB >> 17553881

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.

Patricia M Day1, Cynthia D Thompson, Christopher B Buck, Yuk-Ying S Pang, Douglas R Lowy, John T Schiller.   

Abstract

The mechanisms of human papillomavirus (HPV) neutralization by antibodies are incompletely understood. We have used HPV16 pseudovirus infection of HaCaT cells to analyze how several neutralizing monoclonal antibodies (MAbs) generated against HPV16 L1 interfere with the process of keratinocyte infection. HPV16 capsids normally bind to both the cell surface and extracellular matrix (ECM) of HaCaT cells. Surprisingly, two strongly neutralizing MAbs, V5 and E70, did not prevent attachment of capsids to the cell surface. However, they did block association with the ECM and prevented internalization of cell surface-bound capsids. In contrast, MAb U4 prevented binding to the cell surface but not to the ECM. The epitope recognized by U4 was inaccessible when virions were bound to the cell surface but became accessible after endocytosis, presumably coinciding with receptor detachment. Treatment of capsids with heparin, which is known to interfere with binding to cell surface heparan sulfate proteoglycans (HSPGs), also resulted in HPV16 localization to the ECM. These results suggest that the U4 epitope on the intercapsomeric C-terminal arm is likely to encompass the critical HSPG interaction residues for HPV16, while the V5 and E70 epitopes at the apex of the capsomer overlap the ECM-binding sites. We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553881      PMCID: PMC1951340          DOI: 10.1128/JVI.00552-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

Review 1.  Molecular diversity of heparan sulfate.

Authors:  J D Esko; U Lindahl
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Mechanisms of virus neutralization by antibody.

Authors:  P J Klasse; Q J Sattentau
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

3.  Antibodies that neutralize SIV(mac)251 in T lymphocytes cause interruption of the viral life cycle in macrophages by preventing nuclear import of viral DNA.

Authors:  W Zhuge; F Jia; G Mackay; A Kumar; O Narayan
Journal:  Virology       Date:  2001-09-01       Impact factor: 3.616

Review 4.  Occupancy and mechanism in antibody-mediated neutralization of animal viruses.

Authors:  P J Klasse; Q J Sattentau
Journal:  J Gen Virol       Date:  2002-09       Impact factor: 3.891

5.  Atomic model of the papillomavirus capsid.

Authors:  Yorgo Modis; Benes L Trus; Stephen C Harrison
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

Review 6.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

7.  Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases.

Authors:  H W Virgin; M A Mann; K L Tyler
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

8.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

Authors:  X S Chen; R L Garcea; I Goldberg; G Casini; S C Harrison
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

9.  Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.

Authors:  N D Christensen; N M Cladel; C A Reed; L R Budgeon; M E Embers; D M Skulsky; W L McClements; S W Ludmerer; K U Jansen
Journal:  Virology       Date:  2001-12-20       Impact factor: 3.616

10.  Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Martin Sapp
Journal:  Virology       Date:  2002-08-01       Impact factor: 3.616

View more
  75 in total

1.  A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.

Authors:  Hyunwook Lee; Sarah A Brendle; Stephanie M Bywaters; Jian Guan; Robert E Ashley; Joshua D Yoder; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  [HPV-associated squamous cell carcinogenesis].

Authors:  G Assmann; K Sotlar
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

3.  Usage of heparan sulfate, integrins, and FAK in HPV16 infection.

Authors:  Cynthia Y Abban; Patricio I Meneses
Journal:  Virology       Date:  2010-05-02       Impact factor: 3.616

4.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

5.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

6.  Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.

Authors:  Katherine M Johnson; Rhonda C Kines; Jeffrey N Roberts; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

Review 7.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel.

Authors:  Akiva P Novetsky; Marla J Keller; Ana Gradissimo; Zigui Chen; Stephanie L Morgan; Xiaonan Xue; Howard D Strickler; José A Fernández-Romero; Robert Burk; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2016-09-10       Impact factor: 5.482

9.  Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection.

Authors:  Zurab Surviladze; Rosa T Sterkand; Michelle A Ozbun
Journal:  J Gen Virol       Date:  2015-08       Impact factor: 3.891

10.  Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.

Authors:  Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.